INTRODUCTION
1985 marks the bicentenary of the publication of William Withering's account of his studies on the clinical use of digitalis.' The first part of the present article reviews the use of digitalis before Withering and also the impact that his work had on the use of digitalis in the next hundred years or so. The final two sections deal with work in the present century concerning the clinical use of digitalis and also its mechanism of action. It will become clear that, although an enormous amount of work has been done since Withering, both the therapeutic use and the mode of action are still controversial.
DIGITALIS BEFORE WITHERING'S MONOGRAPH IN 1785
Digitalis purpurea was so named in 1542 by Leonhard Fuchs. It was certainly known and used before the Withering monograph was published. Ointments containing digitalis are mentioned in the Welsh pharmaceutical book Meddygon Myddmacn around 1250, as being good for headaches and spasms. Digitalis pills are described in Hieronymus Bock's Book ofherbs (1546) . In England, digitalis was recommended by John Parkinson (1567-1650) and William Salmon (1644-1713) for treatment of epilepsy, goitre, and tuberculosis, and as an expectorant and an emetic. Salmon published several works on medicinal plants and in one2 mentioned digitalis as providing therapy for dropsy, a disease involving a generalized accumulation of fluid now regarded as a symptom of heart failure. It was included in the Pharmacopoeia Londinensis (1650).
However, before Withering's account, digitalis had fallen almost into disuse. This was largely due to reports of the toxic nature of the drug when taken by mouth. For example, Frangois Salerne in 1748 gave a lecture to the French Academy in Paris, which seems to be the first account of animal experiments using digitalis.3 He described how, after administering digitalis leaves to turkeys and roosters, the animals appeared drunk, had fits, and died. He cautioned "on voit par ces experiences le derangement que l'usage de cette plante peut causer dans les organes *Susan Wray, D.A. Eisner, and D.G. Allen, Department of Physiology, University College London, Gower Street, London WC1E 6BT. Susan Wray, D. A. Eisner, and D. G. Allen appearing just over a hundred years later (1877) . His reputation as a botanist spread all over Europe and he was member of the Linnaean Society. The plant, Witheringia solanacea, is named after him.
Withering had many other scientific interests. He was a scholar of geology, presenting papers to the Royal Society on rocks and soil. Indeed, because of his work distinguishing barium carbonate from barytes (barium sulphate), Werner, a German chemist, in 1796 named barium carbonate as Witherite. Withering also analysed spa water from various sources, including the famous hot springs at Caldas in Portugal, for which he was awarded honorary membership of the Royal Academy of Portugal. Withering, who suffered for a large part of his life from consumption, was in Portugal to escape the English winter and convalesce. At the age of fifty-eight, on 6 October 1799, he died.
WITHERING AND THE FOXGLOVE
In 1775, Withering started collecting case histories on the effects of digitalis in dropsy and ascites (accumulation of fluid in the abdomen). But what had led him to start using internal applications of digitalis at a time when it was little used because of reports of toxic effect? Withering himself explained this in his account.
In the year 1775, my opinion was asked concerning a family receipt for the cure of dropsy. I was told it had long been kept a secret by an old woman in Shropshire, who had sometimes made cures after the more regular practitioners had failed and was informed that the effects produced were violent vomiting and purging; for the diuretic effects seemed to have been overlooked. The medicine was composed of 20 or more different herbs.
He examined the dried leaves microscopically. (His botanical volume contained an account and a picture of the microscope he had designed for the study of botany.) In this way, he noted that the foxglove leaf was present, writing "It was not very difficult for one conversant in these subjects, to perceive, that the active herb could be no other than the foxglove". He determined, therefore, to investigate the effects of digitalis. And he continued that, after noting a few cases, "I ventured to assert in the Botanical Arrangement published the following spring that Digitalis purpurea merited more attention than modern practice bestowed upon it". Withering made notes on his animal experiments, for which, like Salerne, he chose the turkey. His first patients were the poor, who came for advice during his one hour a day which was free of charge. He observed the very powerful diuretic effect of digitalis, but added, "I gave it in doses very much too large and urged its continuation too long". He said that he did not introduce it into his more regular mode of prescription until he heard that Dr Crawley, the principal of Brasenose College, Oxford, had been cured of a hydrops pectoris by foxglove root. Withering included in his account 163 cases he had treated, plus others reported to him by physicians whom he had instructed in its use. He reported all his cases, and so noted that digitalis did not successfully treat all maladies involving accumulation of fluid. The cases of dropsy which he described as having responded well to digitalis were those with the symptoms of atrial fibrillation with oedema. A distinction between dropsy from circulatory or kidney disease was made later by Richard Bright (1789-1858).
Apart from these clinically important details, the most significant point in Withering's book was his attention to dosage. Since the therapeutic dose of digitalis is Two hundred years of the foxglove blood-vessels; but it is conceivable, that a spasmodic state of the vessels secreting urine, or a diseased action in them may be overcome by a remedy, which lessens the force of the general circulation."And again, "I have had occasion to mention, formerly, the utility of digitalis in palpitations of the heart and have known it to remove the complaint entirely . . . even in cases depending on organic laesions of the heart... and rendered life not only longer, but more supportable... and in one remarkable case of [of dropsy] ... the vigour and steadiness of the pulse increased, exactly in proportion as the water was withdrawn from the cellular membrane."
As an index of the interest and knowledge of digitalis, the Medical and Physical Journal ofLondon, vol. 3 in 1800, had nine papers on the foxglove. Medical writers were taking account of digitalis. Thus John Murray wrote in his textbook of materia medica (1804), "of all narcotics, digitalis is that which diminishes most powerfully the action of the system; and it does so without occasioning any previous excitement. Even in the most moderate dose it diminishes the force and frequency of the pulse ... it is one of the most certain diuretics in dropsy apparently from its power of promoting absorption.""3 Kreysig of Saxony in 1814, also postulated a direct effect of digitalis on the heart and blood vessels. However, he assumed that the slowing of the pulse originated in the brain. Johann Evangelista Purkinje (1787-1869), Professor of physiology at Breslau and Prague, described arrhythmias and optical sensation upon the self-administration of foxglove leaves.
An assessment of Withering's publication thirty years on is provided by Dr. John Blackall (1771-1860), who published his own observations on patients with dropsy, including the fact that there is often albumin in the urine."4 He stated "This plant
[foxglove] has certainly made a great addition of late years to our means of cure. For although before the time of Dr. Withering's publication on that subject it has been employed very frequently both in this and other countries as a domestic drug, yet its exhibition was regulated by no sort of principle or distinction and accuracy, as to dose, was wholly out of the question."
The story of digitalis now turns partly into one of declining use. For reasons that are not entirely clear, digitalis became less favoured clinically, although experimental observation continued to be made. One explanation for the decline in clinical usage of digitalis given by Holmstedt and Liljestrand is "the general nihilistic view of therapeutics" which prevailed in the nineteenth century.15 Estes suggests thai, because clinicians at that time believed that dropsy and consumption had very similar pathologies, and consumptives were treated with foxgloves with disappointing results, then faith in digitalis to cure dropsy was shaken.16 This suggestion is amplified by Ackerknecht, who notes how new drugs, such as digitalis, quinine, and iodine, quickly come to be regarded as panaceas.17 As digitalis became used far more often for conditions it could not improve (fevers, epilespsy, scrofula, goitre, nymphomania), this led to scepticism about its use for any condition. Homolle and Querenne published their effort to make purer extracts of digitalis.20 Vulpian, in 1855, was the first to use animal experiments to elucidate the action of digitalis, rather than just to observe the symptoms induced. In frog heart, he showed a slowing of the auricles and muscular contracture of the ventricles. However, the notion that digitalis must act as a "sedative" still persisted, making it difficult to understand its therapeutic value. Then, in 1870, G.W. Balfour of Edinburgh argued that digitalis strengthened the heart and that its action could not be entirely sedative. Milner Fothergill, the next year, said "increased ventricular contraction is the action par excellence of digitalis".21 Diuresis in clinical cases he ascribed to an amelioration of the condition of the circulation. By the beginning of the twentieth century, Elijah Houghton had introduced the standardization of digitalis preparations in the frog. At the end of the nineteenth century, the direct effect of cardiac glycosides (a name given by Gerhardt in 1852) on cardiac contractility was still being overlooked by many investigators, who were more concerned with alterations of rhythm, role of the vagus, and the systolic contracture seen in amphibian hearts. But it was then realized that the heart was the site of digitalis action and the diuresis was a secondary effect. Purer forms of digotoxin were also made. As an example of thinking on digitalis in the 1880s, Karl Binz's (1832-1912) lecture notes of 1884 can be consulted.22 Binz stated that the force of a single contraction of the ventricle can be four to six times greater than normal in digitalis-treated animals. He said how Ludwig Traube referred to this increased action being due to stimulation of the excito-motor nerves, but Binz made the salient point that the result is essentially the same in an isolated heart. He continued, "we know now that digitalis chiefly acts, not by lowering the action of the heart, but by regulating and strengthening it, and that consequently the diminished frequency of the pulse is only a symptom of minor importance." The differential
Two hundred years of the foxglove effect on dropsy due to heart and kidney disease was also known by then. "The effect which digitalis has of equalising the circulation and of removing a state of passive congestion of the kidneys is an important indication for its use as a diuretic. It only acts as such in those cases in which the decrease of the urine, and the dropsy; depend on some heart mischief. Digitalis has no direct action upon the kidney tissue."
In contrast to the interest in the mechanism of action of digitalis, its therapeutic use had not advanced during the nineteenth century. This caused Cushny to write in 1922, "what was written by its [digitalis] advocates in 1810 might have been quoted as representing the general view in 1900. Those who wish to follow the sterile discussions of this period will find some account of them in Meyer's 'Digitalistherapie' ", and "the physician... continued to prescribe digitalis in disease of the heart after the manner of his father and perhaps with less discrimination than his grandfather."23
CLINICAL USE OF DIGITALIS IN THE TWENTIETH CENTURY
By the beginning of the twentieth century, digitalis was established as the mainstay of the treatment of cardiac failure. Its use for most of the other diseases for which it had been promoted during the nineteenth century had been discarded. Changes in the clinical usage of digitalis during the present century have been relatively modest and the purified active principle from digitalis is still used, or at least given a trial, in virtually all cases of heart failure. Because cardiac failure is a common disease and because a cardiac glycoside is often prescribed indefinitely, the cardiac glycosides have become the fourth in the list of most commonly prescribed drugs in the US.'
Formulation of digitalis products
During this century, substantial progress has been made in the formulation of digitalis products. Withering tried a variety of different ways of extracting and storing the active principle and finally made the greatest use of the alcoholic extract or tincture. At the beginning of this century, this practice was gradually being superseded by the use of pills made from powdered digitalis leaf. Naturally, the potency of such tinctures and pills showed great variations, and this meant that the correct dose had to be found by experiment in every patient and that the process had to be repeated whenever one batch of pills or tincture was consumed. An important development, therefore, was the introduction of biological standardization procedures by Houghton in 1886.25 His procedure involved the injection of gradually increasing doses of digitalis into the lymph sac of a frog. The smallest dose which arrested the heart under specified conditions was called a frog-unit. This unit proved rather variable, and the seasonal nature of frogs caused problems, so that a more satisfactory cat-unit was soon introduced.26 Pharmaceutical houses were quick to see the advantages of these procedures and were soon marketing products which had been standardized to contain a specified number of cat-units. 27 Cushny in 1904 stated "digitaline of commerce varies much in composition and in dose, sometimes proving entirely inert, while at other times it has proved poisonous in comparatively small quantities".'8 Not until the 1920s and '30s did the purified preparations of the main active ingredients, digoxin and digitoxin, become available in a sufficiently reliable form for them gradually to supersede the cruder extracts. Digoxin and digitoxin are now the main products used and they are available in sufficient purity to have obviated the need for biological assay. Nevertheless, they are still extracted from foxglove leaves. In the last decade, it has also become possible to measure serum levels easily and cheaply, and this has led to a better understanding of the absorption, metabolism, and excretion without, however, leading to any pronounced changes in clinical practice.29
The value of cardiac glycosides for patients in sinus rhythm
Although the indications for the use of cardiac glycosides have not, in fact, changed dramatically during this century, there have been many investigations and much debate particularly on the question of the value of cardiac glycosides in patients with cardiac failure who are in sinus rhythm. Research in this area has been stimulated by a rapid increase in the understanding of cardiac arrhythmias, particularly at the turn of the century when the electrocardiograph was developed30 and introduced to clinical practice.31 In addition, the gradual development of the clinical trial has offered an objective means of assessing the relative values of different drug treatments or of assessing the relative value of the same drug treatments but in differing clincial situations.
The first edition of Cushny's Textbook of pharmacology (1904) described the major therapeutic value of digitalis as "counteracting certain changes in the circulation which result in blood accumulating in the veins in large quantities".32 The mechanism of action of the drug was the "increased contraction of the ventricles and auricles in systole". This view is backed by a number of original records of contraction of frog and dog hearts (e.g., fig. 1 ) under the influence of digitalis and by an extensive bibliography. Cushny's views on the indications for glycosides and the mechanism of action are suprisingly similar to those current today. He was adamant that the beneficial effects of digitalis were not directly attributable to the slowing of the heart, on the grounds that drugs which simply slowed the heart by an action on the vagus had no such beneficial effect. This is in direct contrast to the ideas promulgated several decades later by Thomas evidence, maintained that the main value of glycosides was to rest the heart during the diastolic period.33
In the first edition of his book, Cushny made no special claims for digitalis in the various types of cardiac failure which were recognized at that time. However, the situation changed quickly when atrial (or auricular) fibrillation was recognized clinically by various figures at the beginning of the century34 and confirmed with electrocardiographic evidence by Lewis (1912 This is a clear expression of the view that digitalis is most effective in patients with atrial fibrillation (fast, irregular pulse). Wenckebach also introduced the idea, which has stimulated much research in this century, that it should be possible to define more closely the categories of patients for whom the cardiac glycosides are relatively effective and ineffective.
The careful case studies of Mackenzie, published in the same year as Wenckebach's paper, also led to the conclusion that digitalis was much more effective in heart failure with atrial fibrillation than when sinus rhythm was present.37 Mackenzie found that cases of heart failure who were in normal rhythm generally had relatively mild symptoms, responded well to bed rest, and showed little if any response to digitalis. It may be that the mild degree of failure in those with sinus rhythm in his study disguised any benefical effect of digitalis. Mackenzie's findings led him to the view that the rapid ventricular rate was a major factor causing heart failure. Lewis endorsed this view, stating "Those who regarded digitalis as a cardiac stimulant mistake its character: its chief action is to rest the heart. To the heart the foxglove is not a tonic but powerfully hypnotic. It controls the diastoles of the heart, it extends the period of sleep."38 The view that digitalis has little value in the treatment of heart failure in sinus rhythm appears in the influential textbooks of Mackenzie (1916) They compared the responses to digitalis of two groups of patients in heart failure, forty-seven with sinus rhythm and thirty with atrial fibrillation. Cardiac failure was diagnosed on the basis of dyspnoea, liver enlargement, pleural effusions, and peripheral oedema, and improvement with digitalis was assessed by regression of these symptoms and signs. Both groups showed comparable improvement in a preliminary period of bed rest. On subsequent treatment with digitalis, 60 per cent of the patients with sinus rhythm improved while 72 per cent with atrial fibrillation improved. However, the proportion of patients showing "great improvement" was only 12 per cent in sinus rhythm but 28 per cent in atrial fibrillation. Thus, their study shows both that digitalis has a substantial beneficial effect in sinus rhythm but that the response in atrial fibrillation is greater. Note that there are substantial numbers of patients in both groups who do not appear to respond.
The debate about the role of cardiac glycosides in heart failure with sinus rhythm is still unresolved.47 Every authority recommends glycosides in heart failure when atrial fibrillation is present. There is much more variability in the recommendations for patients with failure who are in sinus rhythm. Many authorities make no The long-term value of cardiac glycosides A subsidiary argument has developed on the question of whether digitalis should be maintained in the long term. In the past, it has been standard teaching that where digitalis has been effective in the treatment of chronic heart failure then it should be continued indefinitely.5" This view was questioned by Gold, who suggested that "only about 15% of cardiac patients owe to the habitual use of digitalis the fact that they are able to carry on with a reasonable degree of comfort".52 This provoked a short but convincing study by Rogen, who withdrew digitalis from twenty patients with established but controlled failure.53 Sixteen of these showed objective signs of increasing failure (oedema, cyanosis, tachycardia, or visible dyspnoea), which appeared on average after five weeks. The remaining four showed subjective signs of increased failure (fatigue, dyspnoea on exercise) and were given a placebo. Their symptoms did not respond to the placebo and all four subsequently developed objective signs. Thus every patient eventually relapsed. However, all but two of these patients had atrial fibrillation, so that this study confirmed the value of long-term digitalis therapy in atrial fibrillation but did not address the issue for patients with sinus rhythm.
Studies in the last decade have increasingly questioned the value of long-term glycoside therapy for patients in sinus rhythm. A trial by Fleg et al. examined this issue using the full range of modern clinical trial techniques.54 Thirty patients with established heart failure who were in sinus rhythm entered the trial. At entry all patients were on maintenance glycoside therapy -and the majority were using a diuretic. The presence of compensated heart failure was established from clinical symptoms, limitation of exercise capacity, and investigations of cardiac function. Then for a three-month period the digitalis was either replaced by a placebo or continued at the original dose, though neither the patients nor the doctors directly involved knew which category particular patients belonged to. The other medications were not changed during this period. In a second three-month period, the placebo and the digitalis were reversed. The general result was that withdrawal of digitalis had no significant effect on symptoms or exercise tolerance though some 50 John Hamer, ' The modern management of congestive heart failure', in D.J. Rowlands (editor), Recent advances in cardiology, London, Churchill Livingstone, 1984, vol. 9, pp. 275-288. However, other trials on this issue have given more complicated results. Griffiths et al. studied eleven patients in heart failure who were in sinus rhythm.55 When cardiac glycosides were stopped, one patient showed a pronounced deterioration which rapidly responded to restarting the glycosides: the others were unaffected. These authors reviewed trials on this question and noted that in 341 patients from 10 trials, 16 per cent deteriorated on stopping long-term glycoside treatment. Thus, while many patients can obviously manage without glycosides, there appears to exist a minority who do benefit in the long term. The characteristics of this group remain to be defined; conceivably, they are simply those with the most serious underlying pathology. Griffiths et al. also made the point that most of the trials have shown significant deterioration of cardiac function but this was often unaccompanied by changes in clinical symptoms or signs. The explanation for this finding may rest with the observation that, while cardiac glycosides increase the inotropic state in the presence or absence of cardiac failure, the glycosides only augment cardiac output when cardiac failure is present. Presumably, cardiac output is normally controlled by homeostatic mechanisms and provided cardiac output is within the normal range, an increase in inotropic state produced by a drug is counteracted by a reduction in sympathetic drive.
RESEARCH ON THE MECHANISM OF ACTION OF DIGITALIS IN THE TWENTIETH CENTURY
Before describing more recent ideas on the mechanism of action of digitalis it is necessary to review current ideas concerning the mechanism of contraction of cardiac muscle. Contraction in cardiac muscle depends ultimately on the relative movements of two proteins: actin and myosin. Energy for this is provided by the hydrolysis of adenosine triphosphate (ATP). The principal signal which activates contraction is a rise of the intracellular calcium concentration ([Ca2+] i) from about 0.1 to 5 ,tM and therefore the regulation of the contraction of cardiac muscle depends primarily on the regulation of [Ca2+]j. It is generally thought that, during the heartbeat, the calcium required for contraction is released from an intracellular store, the sarcoplasmic reticulum (s.r.). Relaxation of the heart is produced by the reuptake of Ca ions back into the s.r. The amount of calcium in the s.r. and ultimately therefore the amount that can be released to activate contraction depends on [Cal+]i, which is much less than extracellular calcium concentration. This concentration gradient produces a passive influx of Ca ions into the cell, which is opposed by an active extrusion of Ca ions. One mechanism for producing this is the sodium-calcium (Na-Ca) exchange, which uses the energy provided by Na ions entering the cell down their electrochemical gradient to expel the Ca ions from the cell. Consequently, the level of [Ca2+]i and ultimately force will depend on the transmembrane Na gradient.
The intracellular Na concentration is normally maintained at a low level by the sodium-potassium (Na-K) pump and therefore anything which affects the activity of this pump will ultimately affect contraction.
Two hundred years of the foxglove As mentioned above, by 1900, it had been shown that digitalis could increase the force of contraction of the isolated heart. It was not, however, until 1938 that Cattell and Gold showed that ouabain could increase the force of contraction of an isolated, electrically stimulated, cat papillary muscle.56 One of their records is shown in fig. 2 .
As they pointed out, this experiment eliminated problems present in whole-heart studies where it was difficult to control for effects on coronary blood flow, cardiac size, and heart rate. Work in the twentieth century has therefore turned to the mechanism of the increased cardiac contractility. In 1910, Straub suggested that digitalis acted as a surface active agent and that this reduction of surface tension somehow improved the contractility of the heart.57 However, Clark showed that substances which had much stronger surface-active properties did not increase the force of contraction of the heart.58 Instead, he noted that the actions of strophanthin are similar to those alkalis. Daly and Clark commented that the effects of digitalis could be mimicked by perfusing the heart with a solution of reduced sodium content.59 This observation accords well with modern ideas that the primary action of digitalis is to decrease the transmembrane gradient of Na ions (see below) but, at the time, there was no explanation of the result. It was also noted that the effects of digitalis depended on the presence of calcium in the perfusing solution, and both Burridge' and Loewill suggested that Ca ions might be " M. Cattell and H. Gold, ' far-sighted. It should, however, be noted that it was based on little other than the fact that both calcium and digitalis increase contraction. It is, therefore, easy to understand Cushny, who described this as a "shadowy thesis".6" Since 1930, many hypotheses have been produced for the mechanism of action of the cardiac glycosides, a result of the explosion of work on cell biochemistry and physiology during this period. Indeed, at one time or another, digitalis has been suggested as affecting most stages in the mechanism of cardiac contraction. We will now review some of the suggested mechanisms. (i) Much work had been performed on the control of metabolism and cellular respiration, and it was suggested that the glycosides might act by affecting the energy metabolism of cardiac muscle. In support of this hypothesis, it was found that the concentrations of various metabolites were affected by digitalis. However, it was impossible to exclude the possibility that this was secondary to some other effect rather than being the cause of the positive inotropic action. Certainly, no effect of digitalis could be found on either isolated mitochondria or enzymes. 63 (ii) It was suggested that cardiac glycosides might act by affecting the contractile proteins directly. Robb and Mallov showed that ouabain increased the shortening of actomyosin which was produced by ATP.M Subsequent work even found that the effects of various glycosides on the thixotropy (the decrease of viscosity produced by stirring) of cardiac actomyosin correlated with their biological potency.' However, this observation has not been confirmed, and this explanation has fallen into disrepute. (iii) The intracellular ionic concentrations of muscle cells are very different from those in the surrounding plasma and, in particular, the intracellular concentrations of Na and K are respectively less and greater than those in plasma. It was, therefore, of interest to see whether cardiac glycosides affected the intracellular concentrations of various ions. Harrison et al. found that the intracellular K concentration was decreased by digitalis therapy.66 However, other workers found that digitalis, especially if applied in therapeutic rather than toxic concentrations, could increase intracellular K. Hajdu and Leonard suggested that the inotropic effects of K loss might be produced by a loss of potassium from the cell.67 (iv) It was also suggested that cardiac glycosides could affect the "relaxing factor" of cardiac muscle. This relaxing factor is now known to be the 61 Q. Loewi ( iii) The link between, on the one hand, the demonstration that digitalis inhibited Na and K movements and, on the other, that changes of intracellular Ca rather than Na or K were required to affect contraction was provided by work on the interactions between Na and Ca movements. In 1948, Wilbrandt and Koller73 found that the force of contraction of the frog heart was regulated by the ratio of the extracellular Na to Ca concentrations and, ten years later, this was interpreted as a competition between Na and Ca ions for binding site to activate contraction.74 A further ten years later, Reuter and Seitz showed that the efflux of calcium ions from the mammalian heart depended on the presence of extracellular Na.75 The next year, Baker et al. 76 described an exchange of Na and Ca ions across the membrane of squid axon and pointed out that a similar Na-Ca exchange in cardiac muscle could explain not only the fact that contraction was increased by decreasing the extracellular Na concentration, but also how a rise of intracellular Na ([Na]i) resulting from Na-K pump inhibition would act on Na-Ca exchange to increase intracellular Ca and thence contraction: digitalis --inhibit Na-K pump -[Na+]i Na-Ca exchange T [Ca2+]i T tension Two hundred years of the foxglove as long ago as 1961 by Wilbrandt and Weiss, who found that, although high concentrations of cardiac glycosides inhibited, low concentrations increased the transport of Na ions across frog skin.78 Subsequently, Repke found that low concentrations of glycosides could stimulate a purified Na-K ATPase preparation. 79 Although this stimulatory effect has been often reported, there has been considerable reluctance to accept it. There are probably two reasons for this. First, the stimulatory effect is not always seen and, even in preparations in which it can be demonstrated sometimes, it is a labile phenomenon.80 In contrast, the inhibitory effect (of high concentrations) is perfectly reproducible. Another unresolved question is whether the reported stimulation is a direct effect on the Na-K pump or, alternatively, is produced by an action of the glycoside on nerve terminals which then produces a release of noradrenaline which can indirectly stimulate the Na-K pump.8' Second, even if stimulation could be shown consistently, there is no explanation for how a Na-K pump stimulation could increase the force of contraction. Indeed, on the model presented above, pump stimulation would be expected to decrease rather than to increase the force. It has therefore been suggested (see Noble82 for a review) that the inotropic effect of cardiac glycosides may depend on some other action than the direct effect on the Na-K pump rate To confuse the issue further, we would note that recent work (Isenberg) claims that intracellular injection of cardiac glycosides increases the force of contraction.83 Since binding of cardiac glycosides to the sodium pump occurs at the outside of the cell, this observation would suggest that the Na-K pump may not be directly involved in the inotropic action.
A lot of recent work has been directed to investigating the idea that there may be a naturally occurring endogenous cardiac glycoside in man. It has been reported that a substance isolated from plasma can inhibit the Na-K pump and that this substance is present at greater concentrations in plasma from hypertensive patients. It has been suggested that such an endogenous cardiac glycoside would increase the contraction of arterial smooth muscle and thence increase blood pressure. It has therefore been suggested as one of the causes of essential hypertension. 84 We would end this review by quoting from Glynn who, in 1969, summarized the problem in research on the mechanism of action of cardiac glycosides as follows: "The pharmacologist confronted with the actions of cardiac glycosides is a little like the medieval philosopher confronted with the universe. Many things happen and some things obviously happen as the result of other things, butidentification of the first cause turns out to be rather difficult".85 This statement is still clearly relevant today.
